Carol Lynch
President Sandoz Inc and Head of North America
Meet Carol Lynch
Carol is currently Global Head of Biopharmaceuticals at Sandoz – a business she has successfully managed since September 2014. During this time the business grew rapidly, reached $1 billion in sales annually, and the portfolio came to fruition with 5 biosimilar approvals. Under Carol’s leadership, Sandoz achieved the first approval and launch of a biosimilar in the US, and last year saw the launch of the next wave of biosimilars in the EU. With the recent announcement of Sandoz’s collaboration with Biocon, the company has further strengthened its pipeline. Effective March 1, Carol Lynch succeeded Peter Goldschmidt.